cephalosporin


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia, Wikipedia.
Related to cephalosporin: cephalosporin C

cephalosporin

 [sef″ah-lo-spor´in]
any of a large group of broad-spectrum antibiotics from Acremonium (formerly Cephalosporium), a genus of soil-inhabiting fungi. Cephalosporins are similar in structure and antimicrobial action to penicillin. The cephalosporins have been classified by “generations” according to general features of antimicrobial activity, with successive generations having increasing activity against gram-negative organisms and decreasing activity against gram-positive organisms.

ceph·a·lo·spo·rin

(sef'ă-lō-spōr'in),
Antibiotic produced by a Cephalosporium, but after the antibiotic was discovered the name Cephalosporium was changed to Acremonium.

cephalosporin

/ceph·a·lo·spo·rin/ (sef″ah-lo-spor´in) any of a group of broad-spectrum, penicillinase-resistant antibiotics from Acremonium, related to the penicillins in both structure and mode of action. Those used medicinally are semisynthetic derivatives of the natural antibiotic cephalosporin C. First-generation cephalosporins have a broad range of activity against gram-positive organisms and a narrow range of activity against gram-negative organisms; second-, third-, and fourth generation agents are progressively more active against gram-negative organisms and less active against gram-positive organisms.

cephalosporin

(sĕf-ə-lə-spôr′ĭn)
n.
Any of various beta-lactam antibiotics, derived from the fungus Acremonium chrysogenum or made semisynthetically, used to treat a wide range of bacterial infections.

cephalosporin

Infectious disease Any of a family of broad-spectrum tetracyclic triterpene antibiotics derived from Cephalosporium spp, which are similar chemically and in mechanism of action to penicillin Indications Skin and soft tissue infections, RTIs, UTIs, STDs, meningitis, endocarditis, septicemia of unknown portal of entry, anaerobic infections, polymicrobial infections Pharmacokinetics Absorbed orally, excreted by the dustributed in tissues Adverse reactions Hypersensitivity, rash, serum sickness, acute tubular damage. See Fourth-generation cephalosporin.
Cephalosporin generations
1st
IV agents–Cephalothin, cephaloridine
2nd
Oral agents, which had a longer half-life
3rd
↑ antibacterial spectrum to include H influenzae, anaerobic bacteria, eg Bacteroides fragilis
4th
Not all authors use the term ; further; ↑ antibacterial spectrum to include Pseudomonas species<</dd>
.

ceph·a·lo·spo·rin

(sef'ă-lō-spōr'in)
Antibiotic produced by a Cephalosporium, but after the antibiotic was discovered the name Cephalosporium was changed to Acremonium.

cephalosporin

One of a range of antibiotics first obtained from a Cephalosporium fungus found in the sea near a sewage outflow. Their chemical structure is very similar to that of the penicillins and many semisynthetic forms have been developed. Their toxicity is low and they are effective against a wide range of organisms. Unfortunately, the spelling of cephalosporin drug names shows an apparently arbitrary distribution of ‘ceph’, ‘cep’ and ‘cef’, with a strong tendency to the latter, assisted by the recent requirement to adopt European nomenclature regulations.

antibiotic 

1. Pertaining to the ability to destroy or inhibit other living organisms.
2. A substance derived from a mould or bacterium, or produced synthetically, that destroys (bactericidal) or inhibits the growth (bacteriostatic) of other microorganisms and is thus used to treat infections. Some substances have a narrow spectrum of activity whereas others act against a wide range of both gram-positive and gram-negative organisms (broad-spectrum antibiotics). Antibiotics can be classified into several groups according to their mode of action on or within bacteria: (1) Drugs inhibiting bacterial cell wall synthesis, such as bacitracin, vancomycin and the β-lactams based agents (e.g. penicillin, cephalosporins (e.g. ceftazidime, ceftriaxone, cefuroxime). (2) Drugs affecting the bacterial cytoplasmic membrane, such as polymyxin B sulfate and gramicidin. (3) Drugs inhibiting bacterial protein synthesis, such as aminoglycosides (e.g. amikacin sulfate, framycetin sulfate, gentamicin, neomycin sulfate and tobramycin), tetracyclines, macrolides (e.g. erythromycin and azithromycin) and chloramphenicol. (4) Drugs inhibiting the intermediate metabolism of bacteria, such as sulfonamides (e.g. sulfacetamide sodium) and trimethoprim. (5) Drugs inhibiting bacterial DNA synthesis, such as nalixidic acid and fluoroquinolones (e.g. ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin and ofloxacin). (6) Other antibiotics such as fusidic acid, the diamidines, such as propamidine isethionate and dibrompropamidine. Syn. antibacterial. See antiinflammatory drug; fusidic acid.

ceph·a·lo·spo·rin

(sef'ă-lō-spōr'in)
Antibiotic produced by a Cephalosporium.
References in periodicals archive ?
by restricting access to third-generation cephalosporins in favor of drugs recommended by the hospital antimicrobial drug policy) but did not aim to shorten the duration of treatment.
The adverse event profile of Cefotetan for Injection is similar to that of other cephalosporin antibiotics.
The order does not limit the use of cephapirin, an older cephalosporin drug that is not believed by FDA to contribute significantly to antimicrobial resistance.
6% efficacy against bacteria strains resistant to the cephalosporin component alone[2].
Imposing restrictions on products with combinations of resistance, such as simultaneous resistance to quinolones and cephalosporins in Salmonella, as reported in this study, would be a good first step towards managing antimicrobial drug-resistance risks.
We analyzed cephalosporin resistance in pneumococcal nasopharyngeal isolates collected from 1994 to 1995 from patients with sickle cell disease in Memphis, a time and place corresponding to the initial description of the highly cephalosporin-resistant [TN.
The Company will initiate clinical trials in November 2008 to evaluate this drug, a third generation Cephalosporin antibiotic combined with a bacterial-enzyme inhibitor, for the treatment of infections.
Cerexa expects to initiate Phase 2 clinical trials with PPI-0903, a next-generation, broad-spectrum cephalosporin antibiotic with methicillin-resistant Staphylococcus aureus (MRSA) coverage, in the second half of 2005.
Dragon Pharmaceutical, headquartered in Vancouver, Canada, is a leading manufacturer and distributor of a broad line of high-quality antibiotic products including 7-ACA, a key intermediate to produce cephalosporin antibiotics, clavulanic acid, and formulated cephalosporin antibiotic drugs.
Variables predicting third-generation cephalosporin resistance were surgery (p = 0.